The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 744 Metabolic Health articles
The viral term 'Ozempic penis' suggests semaglutide increases size, but urologists clarify it's a visual illusion from fat loss. We explore the real, complex effects of GLP-1 medications on sexual health, from potential erection improvements to libido changes.
A groundbreaking study reveals that Ozempic and other GLP-1 medications like semaglutide significantly lower risks of depression, anxiety, addiction, and even suicidal behavior. Analyzing nearly 100,000 people, researchers found up to 47% reductions in related hospital visits and work absences. This could transform treatment for those with overlapping metabolic and mental health issues.
Ozempic and other GLP-1 medications promise weight loss and health gains, but they're fueling toxic body image problems in the gay community. Queer celebs like Margaret Cho and Boy George are praising the drugs, yet experts highlight risks to body confidence and even the ability to bottom. No studies yet focus on LGBTQ+ users, but the impacts are real.
Single mum Rebecca Tidy transformed her life by losing six stone on Mounjaro, but the real game-changer was the confidence boost that doubled her income. After ditching Saxenda due to side effects, Mounjaro helped her reclaim control. Here's her inspiring journey from exhaustion to empowerment.
The latest Morning Squawk highlights the Dow's ongoing losing streak, climbing fertilizer prices, and Novo Nordisk's new Wegovy shot amid market volatility. President Trump ramps up criticism of Fed Chair Jerome Powell, urging continued investigation into the 'incompetent' leader. A judge's subpoena block adds tension to Trump's Fed nominee confirmation.
Jefferies has reiterated its Buy rating on Eli Lilly stock with a $1,300 price target, citing encouraging GLP-1 prescription data for the week ending March 13. Oral Wegovy showed strong performance in its 10th launch week, outpacing comparable injectables like Zepbound and Wegovy. Meanwhile, other GLP-1s saw slight declines amid Lilly's promising pipeline.
More than 10% of U.S. adults use GLP-1 drugs like Ozempic and Wegovy, but one in seven microdose for longevity without major weight loss or side effects, per Evidation survey. Biohackers and clinics like AgelessRx promote it for reducing inflammation and chronic disease risks. Yet experts caution on unproven claims and sourcing risks.
A venomous desert lizard, the Gila monster, holds a surprising key to one of medicine's biggest breakthroughs: Ozempic. Its venom revealed exendin-4, a stable GLP-1 mimic that paved the way for transformative diabetes therapies. This unlikely origin story highlights nature's role in modern metabolic health.
As GLP-1 medication use surges, a Weight Watchers report reveals medication alone isn't enough for lasting weight loss. Weight Loss Buddy emerges as a vital tool, combining AI-driven guidance and peer accountability to boost adherence and outcomes. This shift highlights the need for behavioral infrastructure in obesity treatment.
